Disease management and medication compliance

Population Health Management

Volumn 15, Issue 1, 2012, Pages 20-28

  Cohen, Joshua ^a   Christensen, Kathyrn ^a   Feldman, Lanna ^a  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CYSTIC FIBROSIS; DEVICES; DIABETES MELLITUS; DISEASE MANAGEMENT; HEALTH CARE ORGANIZATION; HEALTH INSURANCE; HEALTH PROGRAM; HEALTH SURVEY; HUMAN; HYPERLIPIDEMIA; PATIENT COMPLIANCE; PATIENT IDENTIFICATION; PRACTICE GUIDELINE; RISK ASSESSMENT; RISK FACTOR; SCREENING TEST;

CYSTIC FIBROSIS; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; FEMALE; GUIDELINE ADHERENCE; HEALTH STATUS INDICATORS; HUMANS; HYPERLIPIDEMIAS; INTERVIEWS AS TOPIC; MALE; MEDICATION ADHERENCE; QUESTIONNAIRES; SELF CARE;

EID: 84856888016     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2011.0020     Document Type: Article

References (42)

1. Cramer JA, Roy A, Burrell A, et al. Medication compliance and persistence: Terminology and definitions. Value Health. 2008;11:44-47. (Pubitemid 351160875)
2. Balkrishnan R. The importance of medication adherence in improving chronic-disease related outcomes: What we know and what we need to further know. Med Care. 2005;43: 517-520. (Pubitemid 40847287)
3. Cutler D, Everett W. Thinking outside the pillbox- Medication adherence as a priority for health care reform. N Engl J Med. 2010;362:1553-1555.
4. New England Healthcare Institute. Thinking outside the pillbox: A system-wide approach to improving patient medication adherence for chronic disease.2009. Available at: Http://www.nehi.net/publications/44/thinking- outside-the-pillbox-a-systemwide-approach-to-improving-patient-medication- adherence-for-chronic-disease. Accessed October 30, 2010.
5. Martin LR, Williams S, Haskard KB, Dimatteo MR. The challenge of patient adherence. Ther Clin Risk Manag. 2005; 1:189-199.
6. Centers for Disease Control and Prevention. Chronic disease prevention and health promotion. 2010. Available at: Http:// www.cdc.gov/chronicdisease/ overview/index.htm. Accessed July 10, 2010.
7. Anderson C. Chronic Conditions: Making the Case for Ongoing Care. Baltimore, MD: Johns Hopkins University, Partnership for Solutions; 2002.
8. Sabate E. Adherence to long-term therapies: Evidence for action. Geneva: World Health Organization; 2003.
9. Yeaw J, Benner J, Walt J, Sian S, Smith D. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2010;15:728-740.
10. Fogarty J, Youngs G. Psychological reactance as a factor in patient non-compliance with medication taking: A field experiment. J Appl Soc Psych. 2000;30:2365-2391. (Pubitemid 33267904)
11. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein M, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288:455-461. (Pubitemid 34787476)
12. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med. 2005;353:487-497. (Pubitemid 41127293)
13. Ho PM, Rumsfeld JS, Masoudi F, et al. Effect of medication non-adherence on hospitalization and mortality among patients with diabetes mellitus. Arch Int Med. 2006;166: 1836-1841. (Pubitemid 44455165)
14. National Council on Patient Information and Education Coalition. Enhancing prescription medicine adherence: A national action plan. Available at: Http://www.intelecare com/downloads/ncpie-adherence-report.pdf. Accessed September 2, 2010.
15. Quittner AL, Espelage DL, Ievers-Landis C, Drotar D. Measuring adherence to medical treatments in childhood illness: Considering multiple methods and sources of information. J Psych Med Settings. 2000;7:41-53.
16. Farmer K. Methods for measuring and monitoring medication regimen adherence in clinical trials and clinical practice. Clin Therapeutics. 1999;21:1074-1090. (Pubitemid 29326165)
17. Norell SE. Accuracy of patient interviews and estimates by clinical staff in determining medication compliance. Soc Sci Med. 1981;15:57-61. (Pubitemid 11157936)
18. Linden A, Roberts N. A user's guide to the disease management literature: Recommendations for reporting and assessing program outcomes. Am J Manag Care. 2005;11: 113-120. (Pubitemid 40250539)
19. Quittner AL, Modi A, Lemanek K, Ievers-Landis CE, Rapoff MA. Evidence-based assessment of adherence to medical treatments in pediatric psychology. J Ped Psych. 2008;33: 916-936.
20. Felland LE, Reschovsky J. More non-elderly Americans face problems affording prescription drugs. Available at: Http:// www.hschange.com/CONTENT/ 1039/. Accessed September 12, 2010.
21. Safran D, Neuman P, Schoen C, et al. Prescription drug coverage and seniors: Findings from a 2003 national survey. Health Aff. 2005;Suppl Web Exclusive:W5-152-W5-166.
22. Coleman K, Mattke S, Perrault PJ, Wagner EH. Untangling practice redesign from disease management: How do we best care for the chronically ill? Ann Rev Pub Health. 2009; 30:385-408.
23. Wennberg D, Marr A, Lang L, O'Malley S, Bennett G. A randomized trial of a telephone care management strategy. N Engl J Med. 2010;363:1245-1255.
24. Shapiro R, Moreno L. Disease management technologies: User needs can guide decision making. Available at: Http://www.mathematica-mpr.com/ publications/pdfs/ diseasemanagetech.pdf. Accessed October 1, 2010.
25. Hepke KL, Martus M, Share DA. Costs and utilization associated with pharmaceutical adherence in a diabetic population. Am J Manag Care. 2004;10:144-151. (Pubitemid 38332389)
26. Chernew ME, Juster I, Shah M, et al. Evidence that valuebased insurance can be effective. Health Aff. 2010;29: 530-536.
27. Mays GP, Au M, Claxton G. Convergence and dissonance: Evolution in private-sector approaches to disease management and care coordination. Health Aff. 2007;26:1683-1691.
28. Holtz-Eakin D. An analysis of the literature on disease management programs. Available at: Http://www.cbo.gov doc.cfm?index=5909&type=0. Accessed August 11, 2010.
29. Mattke S, Seid M, Ma S. Evidence for the effect of disease management: Is $1 billion a year a good investment? Am J Manag Care. 2007;13:670-676. (Pubitemid 350294568)
30. Flume P, Sullivan B, Robinson K, et al. Cystic fibrosis pulmonary guidelines: Chronic medications for maintenance of lung health. Am J Respir Crit Care Med. 2007;176:957-969. (Pubitemid 350127838)
31. Kaiser Permanente Care Management Institute. Adult diabetes clinical practice guidelines. Oakland CA: Kaiser Permanente Care Management Institute, 2009.
32. National Cholesterol Education Program Expert Panel. Detection, evaluation, and treatment of high blood cholesterol in adults. NIH Publication No. 01-3670. Washington, DC: National Institutes of Health, 2001.
33. Cohen J, Chee J. Pharmaceutical benefit managers' role in facilitating Medicare beneficiary access to pharmaceutical care. Dis Manag Health Outcomes. 2002;10:221-227. (Pubitemid 34454674)
34. Chernew ME, Shah M, Wegh A, et al. Impact of decreasing co-payments on medication adherence within a disease management environment. Health Aff. 2008;27:103-112. (Pubitemid 351198595)
35. Sipkoff M. Spend a little more on selected patients for payoff down the line. Manag Care. 2009;18:20-22.
36. Cohen J. Are commercial disease managers willing and prepared to enter the Medicare market? Drug Inf J. 2002; 36:445-452.
37. Cohen J, Paquette C. Impact of disease management on costeffectiveness of Medicare spending. Drug Inf J. 2003;37: 329-339. (Pubitemid 37305445)
38. Fendrick AM, Chernew ME, Levi G. Value-based insurance design: Embracing value over cost alone. Am J Manag Care. 2009;15:S277-S283.
39. Diamond F. Disease management grows, though under fire. Manag Care. 2010;19:12-16.
40. Linden AL. What will it take for disease management to demonstrate a return on investment? New perspectives on an old theme. Am J Manag Care. 2006;12:217-222.
41. Behling C. The ghosts of disease management. Pop Health Manag. 2010;13:57-58.
42. Chen S, Levin R, Gartner J. Medication adherence and enrollment in a consumer-driven health plan. Am J Manag Care. 2010;16:43-50.